Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

As obesity rates in the United States have reached 41.9 percent among adults, Xevant has released a new e-book, Navigating Obesity Care and GLP-1 Coverage: A Guide for Employers, designed to empower ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Results among Omada members taking GLP-1s for weight loss who entered into a discontinuation care track (n=63) showed that, on average, members were able to successfully maintain their weight 16 weeks ...

Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretio ...

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

With one in eight Americans having taken a GLP-1 already — including 43% of those ... that have helped other patients offset the high cost of GLP-1s. As GLP-1s become more integrated into ...